ARQT — Arcutis Biotherapeutics, Inc.

Summary of Arcutis Biotherapeutics Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Net Product Revenues: $127.5 million, an 84% increase year-over-year and a 29% increase sequentially from Q3 2025.
• Full Year 2025 Net Product Revenues: $372.1 million, up 123% from 2024.
• Gross to Net: Stable in the 50s; anticipated to remain consistent in 2026.
• Net Income: $17.4 million for Q4, compared to a net loss of $10.8 million in Q4 2024.
• Cash Flow: Positive cash flow from operations of $26.2 million in Q4 2025; cash and marketable securities balance of $221.3 million as of December 31, 2025.
• R&D Expenses: Increased to $20.5 million in Q4, reflecting ongoing clinical development.
• SG&A Expenses: Rose to $79 million in Q4, driven by commercialization efforts.

2. Strategic Updates and Business Highlights

• ZORYVE Growth: Strong market share growth, now holding approximately 45% of the branded nonsteroidal topical segment. The product is positioned as a leading alternative to topical steroids for chronic inflammatory skin conditions.
• New Approvals: FDA approvals for ZORYVE foam (0.3%) for psoriasis and ZORYVE cream (0.05%) for atopic dermatitis in children aged 2-5, expanding treatment options.
• Sales Force Expansion: Increased dermatology sales force by 20% and initiated a new team targeting primary care physicians and pediatricians.
• Clinical Development: Completed enrollment in the Phase II INTEGUMENT-INFANT trial for infants with atopic dermatitis, reporting positive results. Initiated Phase II studies for vitiligo and hidradenitis suppurativa.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Raised to $480 million - $495 million, reflecting strong momentum and ongoing investments in ZORYVE.
• Positive Cash Flow: Expected to maintain positive cash flow quarterly throughout 2026, despite increased investments in commercialization and R&D.
• Market Access: Improved access to ZORYVE through various insurance plans, including Medicare Part D, with 1/3 of beneficiaries now covered.

4. Bad News, Challenges, or Points of Concern

• Seasonality Impact: Anticipated sequential revenue decline in Q1 2026 due to typical seasonality and deductible resets, which may lead to higher co-pay usage.
• Non-Preferred Drug Position: ZORYVE is classified as a non-preferred drug in Medicare, which could temper demand despite improved access.
• Competitive Pressures: Ongoing competition in the dermatology space, particularly from other topical treatments, necessitating continued focus on differentiation and market share growth.

5. Notable Q&A Insights

• Market Dynamics: Discussion on competitive pressures highlighted Incyte's need to adjust pricing strategies, contrasting with Arcutis's stable pricing and access strategy.
• Pediatric Market Potential: Strong willingness to prescribe ZORYVE in the pediatric segment, with positive feedback from healthcare providers.
• Primary Care Strategy: Emphasis on a targeted approach to primary care and pediatric promotion, focusing on high-volume prescribers to maximize impact without overwhelming the sales force.
• Future Acquisitions: Management expressed a preference to focus on internal growth opportunities rather than pursuing external commercial assets, prioritizing ZORYVE's expansion.

Overall, Arcutis Biotherapeutics demonstrated strong financial performance and strategic advancements in Q4 2025, with a positive outlook for 2026, while also addressing potential challenges in market dynamics and seasonal impacts.